Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Acrivon Therapeutics Inc (ACRV)

Acrivon Therapeutics Inc (ACRV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Acrivon Therapeutics Inc 480 ARSENAL WAY SUITE 100 WATERTOWN MA 02472 USA

www.acrivon.com P: 617-207-8979

Description:

Acrivon Therapeutics Inc. is a clinical stage biopharmaceutical company developing precision oncology medicines which matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon's proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics. The company's lead candidate includes ACR-368. Acrivon Therapeutics Inc. is based in WATERTOWN, Mass.

Key Statistics

Overview:

Market Capitalization, $K 245,472
Enterprise Value, $K 209,452
Shares Outstanding, K 30,877
Annual Sales, $ 0 K
Annual Net Income, $ -60,390 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -16,490 K
EBIT, $ -70,380 K
EBITDA, $ -73,170 K
60-Month Beta 1.24
% of Insider Shareholders 8.50%
% of Institutional Shareholders 71.62%
Float, K 28,252
% Float 91.50%
Short Volume Ratio 0.75

Growth:

1-Year Return -35.58%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.73 on 05/14/24
Next Earnings Date N/A
Earnings Per Share ttm -2.88
EPS Growth vs. Prev Qtr 15.12%
EPS Growth vs. Prev Year -25.86%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ACRV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -49.66%
Return-on-Assets % -45.00%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.70
Book Value/Share 4.77
Interest Coverage -1.86
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar